Effectiveness of Probiotics to Treat End Stage Renal Disease
Status:
Completed
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
Intestinal microbiota has recently emerged as an important player in the progression and
complications of chronic kidney disease(CKD). And drug therapy which selects the gut as a
target has raised lots of concern. It has been reported that the composition of intestinal
flora has changed in uremic patients. Specifically, imbalanced ecosystem has higher number of
pathogens such as Clostridia, Enterobacteria,and lower number of beneficial microbes such as
Lactobacilli and Bifidobacteria. This modification of intestinal flora can strongly increase
transformation of amino acids into Uremic Retention solutes, e.g., indoxyl-sulfate (IS),
p-cresyl sulfate (PCS), which are so called gut-derived uremic toxins. The dysbiosis also
contributes to an increase in intestinal permeability by disrupting the colonic epithelial
tight junction,which may subsequently lead to translocation of endotoxin and bacteria into
the host's internal environment,resulting in systemic micro-inflammation.Also all of these
can promote the progression of renal failure and the incidence of cardiovascular
complications,renal osteodystrophy and anemia.Probiotics is defined by the World Health
Organization as 'live microorganisms that, when administered in adequate amounts, confer a
health benefit on the host'. Probiotics are being increasingly used for various pathologic
conditions.It is said that probiotics have a therapeutic role in maintaining a metabolically
balanced gastrointestinal tract (GIT).And in our previous study,the investigators found that
in uremic rats,lactobacillus acidophilus can relieve bacterial translocation and decrease the
level of inflammatory markers.So our study is mainly designed to investigate whether
probiotics can modulate the balance of intestinal ecosystem, prevent the bacterial
translocation from gut and alleviate the systemic inflammation in hemodialysis(HD) patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University